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Cardiovascular disease (CVD) is among the leading causes of death and disability worldwide. Since its
beginning, the Framingham study has been a leader in identifying CVD risk factors. Clinical trials have
demonstrated that when the modiﬁable risk factors are treated and corrected, the chances of CVD
occurring can be reduced. The Framingham study also recognized that CVD risk factors are multifactorial
and interact over time to produce CVD. In response, Framingham investigators developed the Framingham
Risk Functions (also called Framingham Risk Scores) to evaluate the chance or likelihood of developing
CVD in individuals. These functions are multivariate functions (algorithms) that combine the information
in CVD risk factors such as sex, age, systolic blood pressure, total cholesterol, high-density lipoprotein
cholesterol, smoking behavior, and diabetes status to produce an estimate (or risk) of developing CVD or
a component of CVD (such as coronary heart disease, stroke, peripheral vascular disease, or heart failure)
over a ﬁxed time, for example, the next 10 years. These estimates of CVD risk are often major inputs in
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j.gheart.2013.01.001In this paper, we review brieﬂy the history and original
aims of the Framingham study and, in more detail, the
history of the Framingham Risk Functions. For the latter,
we describe their objectives; the essentials needed for
developing them; the methods of evaluating their perfor-
mance, transportability, and validity in non-Framingham
settings; and their recalibration, if needed, for the valid
use in these non-Framingham settings. Further, we discuss
issues of major current interest involving evaluation of new
and novel biomarkers for improving CVD risk prediction,
long-term risk evaluation, and the concept of heart (or
vascular) age to quantify the state of the vascular system.
Along the way, we review the history and development of
the Framingham Risk Functions for speciﬁc components of
CVD and the more recent expansion to assessing the risk
for global CVD, which includes coronary and cerebrovas-
cular disease and congestive heart failure.
EPIDEMIOLOGIC BACKGROUND AND DESIGN OF
THE FRAMINGHAM HEART STUDY
The Framingham Heart Study is widely acknowledged as
a premier longitudinal cohort study. Several historical
reviews of its early years exist [1e5]. During the decades of
the 1930s to the 1950s, infectious diseases came under
control. The major efforts of public health prior to World
War II were directed at control of these diseases, for they
were the major causes of morbidity and mortality [1,2].
Improved sanitation greatly decreased diarrheal disease.
Strides were made in the control of tuberculosis and pneu-
mococcal pneumonia, and with the introduction of peni-
cillin in 1942, still further dramatic reductions were made.
The problem of the infectious diseases was replaced in the
1940s and 1950s by the mounting epidemic ofGLOBAL HEART, VOL. 8, NO. 1, 2013
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men in the United States developed CVD before reaching the
age of 60 years. Though less prevalent in women, the
development of CVD in women had debilitating and often
fatal consequences [1,2]. Its prevalence was twice that of
cancer. It had become the leading cause of death and the
reason why life expectancy beyond age 45 years did not
increase. Furthermore, there were no known treatments
capable of prolonging life, even in those who managed to
survive an attack. Added to this was the fact that little was
known about the determinants of the disease process itself,
so methods for reversing the epidemic were not even
conjectured.
Action was a needed. There were serious activities in
developing methods to treat and reverse the process of
CVD, but these were still mainly in the conceptual and
development stages. Given the preceding circumstances,
there were many who believed a primary prevention
approach would be promising and possibly more impor-
tant than a search for cures [1]. Dawber [1] presents the
following. Most people will ultimately succumb to some
degenerative disease, including CVD. Complete avoidance
is not possible. However, the onset of CVD might be
delayed by preventive approaches. If the onset could be
delayed, possibly life expectancy could be signiﬁcantly
increased. To develop a preventive approach, the
preventable and modiﬁable pre-disposing factors had to be
identiﬁed. Further, CVD is a disease that is multifactorial
and develops over time, so a longitudinal study was
necessary. To study CVD appropriately, it was necessary to
identify people without CVD, note their lifestyle and
possible other factors such as age and sex, follow them over
time, and relate the factors to the development of CVD. A11
FIGURE 1. Risk of CHD according to elevated blood
pressure (BP), elevated cholesterol, and left ventricular
hypertrophy: Framingham cohort 6-year follow-up.
Elevated BP [ ‡160/95; elevated cholesterol [ ‡260
mg/dl.
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necessary to identify factors and relate them to the devel-
opment of CVD [1,3]. This approach explores, “certain
relationships in health and disease which, with present
technological methods, cannot be observed directly” [3].
The factors that did relate to the development of CVD were
later labeled by Dr. William B. Kannel as CVD risk factors.
The thinking just described led to the initiation of the
Framingham Heart Study (or, because of its breadth over
time, the Framingham study). To achieve the objectives,
a systematic sample of 2 of every 3 families in the town of
Framingham, Massachusetts, was selected. People in those
families between the ages of 30 and 59 years were invited
to participate in the study. Ultimately, 5,209 individuals
(2,336 men and 2,873 women) joined the study. The
major aim of the study was to secure epidemiological data
on CVD. This encompassed the establishment of the rela-
tion of risk factors (e.g., clinical parameters such as age,
sex, blood pressure, cholesterol, body weight, diabetes, and
lifestyle parameters such as smoking, physical activity, and
alcohol consumption) to CVD. Biennial history and phys-
ical examinations were administered in which the risk
factors were evaluated. Procedures such as electrocardiog-
raphy, spirometry, and blood and urine testing were
administered. Continuous surveillance methods identiﬁed
when a CVD event occurred. Clinical and statistical issues
of the relations of risk factors to disease never addressed
before in longitudinal studies were raised and met.
The Framingham study was very successful with an
offspring cohort initiated in 1971 (2,489 men and 2,646
women) and a third-generation cohort in 2001 with over
4,000 subjects [6,7].GENESIS OF MULTIVARIABLE FRAMINGHAM RISK
FUNCTIONS
Originally, the Framingham study examined the relation of
individual risk factors to the development of CVD. Within
a decade of the study, it was clear that the hypothesized
risk factors do contribute to CVD. Further, it became clear
that the presence of multiple risk factors did increase risk.
Figure 1 uses 6-year follow-up data to show the impact of
the joint absence or presence of elevated blood pressure
(blood pressure 160/95 mm Hg), elevated total choles-
terol (260 mg/dl) and the presence of left ventricular
hypertrophy on developing coronary heart disease (CHD).
As early as 1961, Kannel et al. [8], using “risk factor”
explicitly, reported on this 6-year follow-up data and stated
that combinations of the 3 risk factors appear to augment
further the risk of subsequent development of coronary
disease. He then went on to say that as additional longi-
tudinal observations are made, it is hoped that additional
risk factors will be determined. With this, emphasis shifted
to the question as to whether the individual risk factors
could be combined into a multivariate function to give an
assessment (or the probability of or the risk) of developing
a CVD event over a speciﬁc period (say, 10 years). Theoriginal hypothesis of the Framingham study was that CVD
was multifactorial. A multivariable assessment was the
logical consequence. Furthermore, the attention focused
on the development of a primary CVD event (that is, a ﬁrst
CVD event in a person free of CVD at the time of risk factor
evaluation). At this time, the focus was often on the
prediction of CHD. The era of the Framingham Risk
Functions began.BRIEF LISTING OF MAJOR FRAMINGHAM RISK
FUNCTIONS
Dr. William B. Kannel said, “Multivariable risk formula-
tions [now called Framingham Risk Functions or Fra-
mingham Risk Score] for estimating the probability of CVD
conditional on the burden of a number of speciﬁed risk
factors [were and] have been produced to facilitate evalu-
ation of candidates for CVD in need of preventive
management” [9]. The 1960s saw the ﬁrst formal presen-
tation of Framingham Risk Functions, which employed the
statistical technique of discriminant analysis and the then-
new logistic regression analysis, presented for the ﬁrst time
in a computationally doable manner, that was explicitly
devised for computing Framingham Risk Functions
[10e12]. The 1970s and 1980s saw the development of
coronary and general CVD functions [13e15]. The newly
developed statistical methods of survival analysis (time-to-
event analyses) were employed in the 1990s [16e18]. The
Anderson et al. [17] CHD function received major atten-
tion, support, and use from European and U.S. societies.
However, in the United States, what was probably the
Framingham Risk Function that had the ﬁrst real major
impact on guidelines was the Wilson, D’Agostino et al. [18]
primary CHD function, which incorporated explicitly, as
risk factor variables, the risk categories used for cholesterol
[19] and hypertension [20] national guidelines. ThisGLOBAL HEART, VOL. 8, NO. 1, 2013
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TABLE 2. Risk factors for hard CHD model
Sex-speciﬁc (separate models for men and women)
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Framingham Risk Function estimated the risk for general
CHD (angina, myocardial infarction [MI], and coronary
death) over a 10-year period.
Other important Framingham Risk Functions that
have received widespread attention and use are for hard
CHD (coronary death or nonfatal MI) [21], stroke
including transient ischemic attack [22,23], secondary
CHD events [24], intermittent claudication [25], heart
failure [26], stroke or death after atrial ﬁbrillation [27], and
the development of atrial ﬁbrillation [28]. Of special note,
the hard CHD function of D’Agostino, Grundy, et al. [21]
was the motivation of the Framingham Risk Function that
was used for the Adult Treatment Panel III assessment tool
for the risk of hard CHD [29e31].
More recently, the Framingham investigators have
presented a Framingham Risk Function for global CVD
(including CVD death, general CHD, stroke [including
transient ischemic attack], intermittent claudication, and
congestive heart failure) [32]. This function has raised the
question that functions that focused mainly on coronary
disease may be too narrow and a broader outcome is
warranted. The new cholesterol, blood pressure, and die-
tary guidelines will focus on such an approach where hard
CVD (coronary deaths, MI, and stroke) will be the CVD
event of interest.
DEVELOPMENT AND INTERNAL EVALUATION ON
FRAMINGHAM STUDY DATA
The development of the Framingham Risk Functions has
been well documented [8e18,21e33]. Most of these
references do not systematically discuss the steps involved
in developing them and evaluating their performance. In
this section, we give a more detailed presentation of the
issues and methods involved in developing and evaluating
a Framingham Risk Function focusing on how well the
function works on the Framingham data on which it was
developed. Later, we will discuss their transportability.
Table 1 lists 11 issues in development and evaluation of
risk prediction models. We use for illustration the devel-
opment of the hard CHD (coronary deaths and MI) of
D’Agostino, Grundy et al. [21]. In this section, we focus onTABLE 1. Issues in development, evaluation, and validation of
multivariate risk models (internal, external, and extensions)
1. Endpoint (event/outcome)
2. At-risk population
3. Follow-up time
4. Risk factors
5. Mathematical model
6. Estimation (relative and absolute risks)
7. Performance (discrimination, calibration)
8. Internal validation
9. Transporting (performance and recalibration)
10. New markers
11. Long-term prediction (competing risk)
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development of the model. The important components in
the development are to have: 1) a clearly deﬁned component
of CVD that is of clinical relevance and interest such as MI or
coronary death; 2) a clearly deﬁned set of individuals who
are the at-risk population, for example, those free of CVD; 3)
a selected follow-up time such as 10 years; 4) a well-deﬁned
and obtainable set of CVD risk factors such as systolic blood
pressure, total cholesterol, and smoking; 5) a mathematical
model to relate the CVD risk factors to the development of
the disease; and 6) the ability of the model to produce risk
estimates such as relative and absolute risks.
Speciﬁc to the illustration, we have as the ﬁrst step the
selection of the endpoint (event/outcome) for which we
desire to estimate the risk. For the model under discussion,
the endpoint is ﬁrst (primary) hard CHD event.
The second step is the identiﬁcation of the at-risk
population. Framingham Risk Functions are traditionally
sex-speciﬁc. For this particular activity, sex-speciﬁc func-
tions were to be developed. They were derived from 2,439
men and 2,818 women, 30 to 74 years of age who were
free of all CVD at the time of their Framingham study
examination from 1971 to 1974. Participants attended
either the 11th examination of the original Framingham
cohort or the initial examination of the Framingham
Offspring Study. (It should be noted that it is possible that
the at-risk population is the ﬁrst step followed by the
endpoint of interest as the second step.)
Third, the follow-up time is selected. The functions
were developed so that they could be used to produce 10-
year risk estimates. It is useful for the dataset to have
a follow-up that is slightly longer than the desired esti-
mation time. In line with this, 12-year follow-up was ob-
tained on all subjects for the development of hard CHD.
Fourth, the risk factors of the Framingham Risk
Function need to be selected. Table 2 contains the risk
factors. They include age, blood pressure categories, total
cholesterol categories, high-density lipoprotein (HDL) Age (in years, 30 to 74 years)
 Blood pressure (JNC-V)
e Optimal, normal, high normal, stage I hypertension,
stage IIeIV hypertension
 Total cholesterol (NCEP)
e <160, 160e199, 200e239, 240e279, 280
 HDL cholesterol (NCEP)
e <35, 35e44, 45e49, 50e59, 60
 Diabetes
 Smoking
CHD, coronary heart disease; HDL, high-density lipoprotein; JNC-V,
ﬁfth report of the Joint National Committee on Detection, Evalua-
tion, and Treatment of High Blood Pressure; NCEP, National
Cholesterol Education Program.
13
FIGURE 2. Cox model: (A) mathematical model; (B)
general structure of Cox model survival to time t.
TABLE 3. Framingham functions (Cox regression coefﬁcients) hard
CHD model (MI þ coronary death)
Men Women
Age 0.05 0.17
Age2 0.00 0.001
BP
Optimal 0.09 0.74
Normal 0.00 0.00
High normal 0.42 0.37
Stage I hypertension 0.66 0.22
Stage IIeIV hypertension 0.90 0.61
TC
<160 0.38 0.21
160e199 0.00 0.00
200e239 0.57 0.44
240e279 0.74 0.56
280 0.83 0.89
HDL
<35 0.61 0.73
35e44 0.37 0.60
45e49 0.00 0.60
50e59 0.00 0.00
60 0.46 0.54
Diabetes 0.53 0.87
Smoking 0.73 0.98
BP, blood pressure; CHD, coronary heart disease; HDL, high-density
lipoprotein; MI, myocardial infarction; TC, total cholesterol; other
abbreviations as in Table 2.
FIGURE 3. Receiver-operating characteristic curve for
prediction of coronary heart disease: Framingham men.
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14cholesterol categories, smoking behavior (yes/no), and dia-
betes status (yes/no).
Next (step 5), the mathematical model is selected.
Originally, discriminant models were used [10,11]. These
were replaced with logistic regression models [12]. Pres-
ently, time-to-event survival models such as the Cox
proportional hazard regression [18,21e23,32] or acceler-
ated failure models (Weibull) [17,24] are used. Figure 2
displays the Cox model.
For step 6, the mathematical model should have the
capability of supplying the needed estimates of risk. The
Cox model contains a linear function (function L in
Fig. 2B), the coefﬁcients (betas) of which are related to the
hazard ratios (relative risks), which are equal of the
exponential of beta of each risk factor. Further, the Cox
model readily produces an estimation of the absolute risk
of an event occurring within a period from time 0 to time t
(see Fig. 2). In many Framingham Risk Functions, the
absolute risk of interest is the absolute risk at time t ¼10
years. Note, whereas relative risk is essential for the
mathematical model to produce, it is widely accepted that
absolute risk is the risk of interest and that treatment
decisions should be based on absolute risks [34e36].
Table 3 contains the Framingham Risk Function for the
hard CHD as developed previously [21].
After the risk function is developed, it is essential to
evaluate its performance and internal validation. Issue (step)
7 of Table 1 identiﬁes 2 major areas of performancemeasures—discrimination and calibration—for evaluation
of performance. Discrimination refers to the function’s
ability to discriminate cases from noncases. The area under
the receiver-operating characteristic, also called the C-
statistic, is the most used measurement of discrimination
[37e40]. The C-statistic summarizes the sensitivity and
speciﬁcity of the risk function. Figure 3 displays a typical
receiver-operating characteristic curve. The C-statistic has
a probability interpretation, namely it is the probability that
the risk function will assign a higher risk (absoluteGLOBAL HEART, VOL. 8, NO. 1, 2013
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probability) to a randomly selected person who will develop
an event than a randomly selected person who will not. A C-
statistic¼ 0.50 means the function is no better than a guess.
Values above 0.50 indicate discriminatory ability. For
example, a C-statistic ¼ 0.80 indicates that 80% of the time
the risk function will give a higher absolute risk to
a randomly selected person who will develop the disease
than a randomly selected person who will not. Although it is
arbitrary to decide what is a good value of the C-statistic for
a risk function, often a value below 0.70 is considered
suboptimal, a value from 0.70 to 0.80 is considered good,
and a value of 0.80 or above is excellent. For the Framingham
Risk Functions of Table 3, the C-statistics are 0.79 and 0.83
for the male and female functions, respectively, indicating
good to excellent discrimination. It should be noted that the
C-statistic is basically a measure of the risk function to rank
risk. Once good discrimination is established, the evaluation
of its ability to produce the correct absolute risks is important
[37,38]. This is the function of calibration.
Calibration refers to the risk function’s ability to produce
the correct absolute probability. For example, if 15% of
a group of individuals with a particular risk proﬁle develops
CHD over a 10-year period, we want the risk function to
produce a 10-year risk (probability) of 15% for subjects from
that group. Calibration for time-to-event analyses can be
evaluated by the Nam-D’Agostino chi-square test [38]. This
test quantiﬁes the difference between the predicted proba-
bilities versus the estimated event rate in the deciles of risk.
The deciles of risk are generated by listing in order of
magnitude the predicted probabilities and dividing them
into 10 equal groups. Within each decile, the predicted
probabilities are averaged. Furthermore, within each decile,
the Kaplan-Meier estimate for the selected time of follow-up
(often 10 years) is computed [21,38]. These are estimated
event rates. Figure 4 shows a calibration plot contrasting the
predicted probabilities and event rates. The calibration
statistics for Nam-D’Agostino chi-square test are as
follows:FIGURE 4. Calibration plot showing mean risk calibrated
by decile.
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(Kaplan-Meier estimates as observed. Chi-square
distribution with M –1 degrees of freedom). Under the
null hypothesis that the risk model is appropriate, the
test statistics has a chi-square distribution with M e 1
degrees of freedom, where M is the number of categories
(M ¼ 10 when deciles are used). Small values of the chi-
square statistics (as a rule of thumb, less than 20) have
become conventional in deciding the calibration is good.
It should be mentioned that to this day many
investigators developing and evaluating calibration of risk
function do not perform the correct chi-square test. They
often inappropriately use a Hosmer-Lemeshow test [41],
which is appropriate to the logistic regression, not to
a time-to-event risk function. The Nam-D’Agostino chi-
square statistics for the models of Table 3 are,
respectively, 3.3 and 3.7, indicating excellent calibration.
The last aspect of evaluation of the risk model on the
data on which it was generated is interval validation. This is
item 8 of Table 1. It must be anticipated that a model will
ﬁt the data on which it was developed better than it will ﬁt
another dataset. Internal validation attempts to take into
account the overﬁtting that comes from developing a
model on a particular dataset and then evaluating it on the
same data.
Several internal validation procedures have been
proposed and used over the years. These include varia-
tions of split-sample, cross validation, and bootstrapping.
One method often used on Framingham data is a 10-fold
split in which the original sample is randomly divided
into 10 samples; models are ﬁt on all sets of 9 of these
samples; and the resulting 10 models are used individu-
ally to estimate the risks on the 10th samples (the sample
not used in the model development). This procedure
consists of 10 models being developed on the different
sets of 90% of the data, and then each of these being
used to estimate risks on the remaining 10th dataset. The
C-statistic, the calibration plots, and Nam-D’Agostino
calibration statistic are computed on the estimated results.
This procedure was applied to the preceding model
(Table 3) and produced no meaningful differences from
what were given previously for the C-statistics and chi-
square tests.
Some have argued that bootstrapping provides the
best estimate of internal validation at least when applied to
logistic regression models [42]. Framingham investigators
have not found it to give different results from the 10-fold
split for logistic regression or time-to-event models such as
the Cox model. Whereas internal validation is essential,
the best way to validate a prediction/risk model is to apply
it to a new independent dataset. This has been done
extensively to Framingham models and we now turn our
attention to it.15
FIGURE 5. Calibration adjustment for transportation to
a different population. See Harrell et al. [37].
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RISK FUNCTIONS IN NON-FRAMINGHAM
POPULATIONS: EXTERNAL VALIDATION
Framingham investigators have long held that external
validation provides the best evidence of the ability to
generalize with a multivariate risk model [43]. This is item 9
(Transporting [Performance and Recalibration]) of Table 1.
The Framingham Risk Functions were developed in a white
middle-class sample, which raised concerns about whether
these functions can be generalized to other populations
[21]. There were a number of early appraisals (pre-1990) of
the Framingham Risk Functions for CHD on non-
Framingham populations, and these basically found that
the Framingham functions did reasonably well except in
areas in which the incidence of CHD was very low [44e47].
However, even in the low-incidence regions, it was possible
to distinguish people at high risk from those at low risk by
adjusting the intercepts of the discriminant and logistic
models to adjust for the true absolute risk. Since the use of
time-to-event models such as the Cox and Weibull models
(1990 onward), there have been numerous validation
studies of the Framingham Risk Functions by non-
Framingham and Framingham investigators [21,48e59].
Some of the most rigorous external evaluations were those
involving the hard CHD function displayed in Table 3
[21,48,58,59].
In January 1999, a National Heart, Lung, and Blood
Instituteworkshop onCVD risk assessmentwas convened to
address whether Framingham Risk Functions for CHD were
valid in (or could be validly transported to) diverse U.S.
populations. To assess their transportability, they were
compared with those developed from other prospective
studies [21,48]. Sex-speciﬁc Cox regression models were
developed for each U.S. study using the risk factors of
Table 2. The external validation study had 3 major compo-
nents. First, for each of the sex-speciﬁcmodels developed on
the non-Framingham study data, each risk factor’s coefﬁ-
cientwas comparedwith the corresponding coefﬁcient of the
Framingham sex-speciﬁc model of Table 3 and tested if it
was statistically different from the Framingham model
coefﬁcient. Second, the discrimination C-statistic was
computed for each of the sex-speciﬁc models developed.
These C-statistics were compared with the C-statistics ob-
tained by using the sex-speciﬁc Framingham model of
Table 3 to generate absolute risk probabilities. Third, the
Nam-D’Agostino chi-square statistic was computed, again,
for the sex-speciﬁc models developed using the particular
study’s data, and this was compared to the chi-square
computed using the sex-speciﬁc Framingham function of
Table 3. (See D’Agostino, Grundy, et al. [21] and Liu, et al.
[59] for more details on procedure.)
The Framingham Risk Function of Table 3 ﬁt the data
from the ARIC (Atherosclerosis Research in Communities)
study and the PHS (Physicians Health Study) basically as
well as the best function obtained by developing a risk
function directly on their data. For each cohort, as wouldbe expected, the use of the study-speciﬁc risk function was
numerically better in predicting their CHD events than was
the Framingham Risk Function. However, the differences
were usually well within what would be explained by the
overﬁtting of the study-speciﬁc functions. The workshop
concluded that the Framingham Risk Functions could be
used broadly in white population samples in the United
States. Although the blood pressure variable appeared to be
a stronger risk factor in African Americans, the Framing-
ham Risk Functions appeared to apply well to white and
African American population samples [21,48].
In Asian men from Honolulu and Hispanics from
Puerto Rico, the Framingham Risk Functions of Table 3
overestimated the CHD risk. However, a simple calibra-
tion adjustment of the Framingham Risk Models made to
compensate for the lower average baseline risk for CHD
greatly improved their performance [21]. The procedure
for the calibration adjustment is presented in Figure 5. It
consists of replacing the average Framingham underlying
risk (S0[t] of the Cox model [see Figs. 2 and 5]) with the
average event rate for the study estimated by the Kaplan-
Meier estimate [60] and the means of the risk factors
from the Framingham model with the means for the
particular study (see Figs. 2B and 5). See D’Agostino,
Grundy et al. [21] for further elaboration on recalibration.
Of special note related to the recalibration of Fra-
mingham Risk Scores are the adaptations to European
Mediterranean areas [58] and to the CMCS (Chinese Multi-
Provincial Cohort Study) [59]. The latter consisted of
30,121 Chinese adults from 16 centers in 11 provinces of
China and also from Beijing, ages 35 to 64 years at base-
line, and who were followed for up to 10 years (follow-up
rate of 86%). Figures 6 and 7 show the results of the
discrimination and calibration comparison, respectively, of
the best Cox regression risk function computed on women
from the CMCS to the Framingham Risk Function of
Table 3 applied to the female CMCS data. The C-statistics
are 0.759 and 0.742, respectively (Fig. 6). The value of the
Nam-D’Agostino chi-square statistics is 147.6 for the
Framingham Risk Function applied directly to the CMCSGLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 11-23
FIGURE 6. C-statistics for women in the Chinese Multi-
Provincial Cohort Study (CMCS) and Framingham Heart
Study (FHS).
gREVIEWjdata. After recalibration, it is 16.9. The chi-square statistic
applied to the best CMCS model is 14.2 (Fig. 7).
Four useful references dealing with development,
performance evaluation, and validation are D’Agostino,
Grifﬁth, and Schmidt [61], Brindle, May et al. [62], Barzi
et al. [52], and Whittemore [63]. These offer both general
ideas and speciﬁc examples.RISK FUNCTIONS IN TREATMENT GUIDELINES
CHD is the most common outcome of Framingham stan-
dard risk functions. It equals all the other CVD manifes-
tations in incidence and is the most lethal. As was
mentioned earlier, much of the attention and focus of
Framingham investigators was directed at developing risk
functions for CHD [10,13,15,17,18,21]. These efforts
culminated in the development of the Adult TreatmentFIGURE 7. Chi-square calibration for women in the Chinese
Heart Study (FHS).
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contains explicitly all the input needed to use the func-
tion for men. The risk factor variables include logs of age,
total cholesterol, HDL cholesterol, and systolic blood
pressure. Also, it contains a dichotomous variable for blood
pressure medication (yes/no), smoking (yes/no), and
interaction variables with the log age. It produces 10 year
absolute probability estimates of the risk of developing
hard CHD (coronary death or MI).
This function was developed to evaluate if a patient was
suitable for statin therapy. The ATP III guidelines classify
people into high risk (CHD or a CHD equivalent or 2 or
more risk factors and 10-year risk greater than 20%),
moderately high risk (10-year risk between 10% and 20%
and 2 or more risk factors), moderate risk (10-year risk less
than 10% and 2 or more risk factors), and low risk (0 or 1
risk factors). Based on these risk categories, treatment
recommendations are made [29]. It should be mentioned
that the Framingham ATP III function and other major
Framingham Risk Functions are available on the
FraminghamWeb page including formula and Excel spread
sheets (Microsoft, Redmond, Washington, USA) [64].RISK PREDICTION FOR GLOBAL CVD
Whereas CHD is a major component of overall CVD, it
does not include other important manifestations such as
stroke, heart failure, and peripheral arterial disease.
Framingham investigators have considered that for risk
functions, a broader class of CVD components would be
appropriate, especially for public health. In line with this in
2008, Framingham investigators presented a global CVD
risk function for estimating the risk of developing any
manifestations of CVD (including CHD, cerebrovascular
disease, intermittent claudication, and congestive heart
failure) [32]. The global CVD function produces an abso-
lute risk estimate for global CVD and, by simple adjust-
ments, the risk for any of the components of CVD [32].
Table 5 is the score sheet for the female global CVD
function, which also can be used to obtain absolute risks
of CVD. As an example, for a woman age 61 years, with
HDL of 47, total cholesterol of 230, nontreated systolicMulti-Provincial Cohort Study (CMCS) and Framingham
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TABLE 4. ATP III hard CHD function for men
Independent Variables Coefﬁcient Means
Ln (age) 52.009610 3.8926095
Ln (total) 20.014077 5.3441475
Ln (HDL-C) 0.905964 3.7731132
Ln (SBP) 1.305784 4.8618212
TRT for HTN (SBP >120) 0.241549 0.1180474
Current smoker 12.096316 0.3356020
Ln (age)Ln (total) 4.605038 20.8111562
Ln (age)smoker 2.843670 1.2890301
Ln (age)Ln (age) 2.933230 15.2144965
Average 10-year survival ¼ 0.940200
ATP III, Adult Treatment Panel III; CHD, coronary heart disease; total,
total cholesterol; HDL-C, high-density lipoprotein cholesterol; HTN,
hypertension; SBP, systolic blood pressure; TRT, treatment.
j gREVIEW
18blood pressure of 124, and who is a nonsmoker and
nondiabetic, the corresponding points are 9, 0, 3, 0, and
0 for a total of 12 points, which corresponds to a 10-year
risk of CVD of 8.6%. For comparison, the ATP III function
produces for this woman a 10-year risk of developing
a hard CHD of 3%.TABLE 5. CVD points and risk for women
CVD Points
Points Age HDL Total Cholesterol
3
2 60þ
1 50e59
0 30e34 45e49 <160
1 35e44 160e199
2 35e39 <35
3 200e239
4 40e44 240e279
5 45e49 280þ
6
7 50e54
8 55e59
9 60e64
10 65e69
11 70e74
12 75þ
Points allotted
CVD Risk
Points Risk Points Risk
2 or less Below 1% 4 2.4%
1 1.0% 5 2.8%
0 1.2% 6 3.3%
1 1.5% 7 3.9%
2 1.7% 8 4.5%
3 2.0% 9 5.3%
CVD, cardiovascular disease; HDL, high-density lipoprotein; SBP, systolic bloThe global CVD function was not developed to replace
the risk functions for individual CVD components, but
rather to bring unity to the subject. First, it deals with
primary prevention. That is, the person is free of any
manifestation of CVD. Second, it can produce a risk esti-
mate of CVD along with estimates of the separate
components of CVD. It supplies a full assessment across
the spectrum of CVD.SCORE SHEETS VERSUS MATHEMATICAL MODEL’S
ESTIMATES
Whereas Table 5 can be used to produce a 10-year
estimate of CVD, the Framingham Risk Functions are
based on a mathematical model such as the male ATP III
model of Table 4. Most of the risk functions are based on
Cox regression models [38]. The score sheet is only an
approximation to the mathematical function. Excel
programs have been developed to produce the risk based
on the mathematical functions. These are available on the
Framingham Website [64]. A score sheet for the global
CVD function was used to illustrate multivariate relations
among risk factors. For estimating risk estimates inSBP Not Treated SBP Treated Smoker Diabetic
<120
<120
120e129 No No
130e139
140e149 120e129
130e139 Yes
150e159 Yes
160þ 140e149
150e159
160þ
Points Risk Points Risk
10 6.3% 16 15.9%
11 7.3% 17 18.5%
12 8.6% 18 21.5%
13 10.0% 19 24.8%
14 11.7% 20 28.5%
15 13.7% 21þ Above 30%
od pressure.
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practice, we strongly suggest the use of the Excel
programs.
ADDING NEW RISK FACTORS TO RISK FUNCTIONS
CVD often occurs in people with what is considered
acceptable or average risk factors values. This suggests that
there are other risk factors that must be responsible and
which, if added to the present set of CVD risk factors, would
improve risk estimation. A number of risk factors (some new
and often called novel risk factors) have been proposed.
Among these are inﬂammatory markers such as C-reactive
protein, coronary calcium, lipoprotein (a), interleukin-6,
ﬁbrinogen, homocysteine, small-dense low-density lipo-
protein, insulin resistance, metabolic syndrome, function
assess by tissue-type plasminogen activator and plasminogen
activator inhibitor 1 antigens, platelet function, and genetic
scores [65e76]. These new variables, for the most part, have
had little effect on changing the discrimination C-statistics.
There have been some positive results. Polak et al. [75]
showed that the carotid-wall intima-media thickness does
add signiﬁcantly to CVD prediction. Furthermore, coronary
artery calcium scores also appear to add signiﬁcantly [76].
There seems to be at least 2 major problems. First,
once the C-statistic is in the range of 0.75, it is very hard
mathematically to improve it. It is conﬁned to the range 0.5
to 1.0. Even when the change in the C-statistic is statisti-
cally signiﬁcant, it appears numerically often to be trivial.
Second, the procedure often used for testing if the
C-statistic increases has been misused; signiﬁcant changes
were possibly not recognized [77,78].
For evaluating a new risk factor, an approach that did
not focus solely on the change in the discrimination
C-statistic was needed. Emphasis shifted to asking if a new
risk factor could reclassify subjects that improve risk esti-
mation. For example, in the ATP III model classiﬁcations
mentioned earlier, would C-reactive protein shift a person
appropriately from a moderate- to high-risk category?
Framingham has contributed substantially to this effort.
Pencina, D’Agostino, and other Framingham investigators
have produced a number of papers dealing with this
reclassiﬁcation concept [40,79e83]. Pencina, D’Agostino,
Sr., D’Agostino, Jr., and Vasan [79] deﬁned 2 statistics to
measure the new risk factors’ ability to improve prediction.
The Net Reclassiﬁcation Index measures how much more
reclassiﬁcation is appropriate (moves those who will
develop events into higher categories) versus inappro-
priate, so that reclassiﬁcation can be attributed to the new
risk factor. The Integrative Discrimination Index is basi-
cally a measurement of how the R2 (explained variance)
improves with the addition of the new risk factor. These
measures do have solid interpretations, and quantiﬁcation
of meaningful improvements is now possible [81e83].
LIFETIME AND LONG-TERM RISK FUNCTIONS
In addition to short-term (up to 10 years) risks, Framing-
ham investigators have had an interest in lifetime and long-GLOBAL HEART, VOL. 8, NO. 1, 2013
March 2013: 11-23term (for example, 30 years) risk estimation. In 1997,
Seshardri et al. [84] published a paper on the lifetime risk of
dementia and Alzheimer’s disease. Methodologically, this
paper identiﬁed the need to consider competing risks (such
as death from other causes) when generating long-term
estimates of the effect of risk factors. Given its impor-
tance, a methodological paper, including a computer macro
was published in 2002 by Beiser et al. [85]. Lifetime risk
estimation work was extended to CVD, led by Drs. Donald
Lloyd-Jones and Daniel Levy, and resulted in a number of
important papers on the lifetime risk of CHD, congestive
heart failure, and atrial ﬁbrillation [86e89]. These papers
basically consisted of identifying a group of individuals and
following them for an extended period. They did not have
the feature of looking at a number of risk factors and eval-
uating the impact of these on the long-term outcomes as did
the 10-year Framingham Risk Functions such as the hard
CHD and ATP III functions of Tables 3 and 4. To address
this, Pencina, D’Agostino, Larson et al. [90] generated risk
models for estimating the risk of CVD over a 30-year period.
For a subject between the ages of 20 and 40 years, a 30-year
risk can be computed that relates the standard CVD risk
factors at baseline to the development of developing CVD
over the next 30 years.
The need and usefulness of a long-term risk is
becoming recognized as an important addition to risk
estimation [91]. Many individuals have a low 10-year CVD
risk, but a substantial 30-year risk, such as a 30-year-old
woman with total cholesterol of 250 and other risk factors
at normal levels, who would have a 10-year risk lower than
10%. Incorporating long-term risk estimation in the eval-
uation of this individual could lead to better care. For
example, a subclinical test may be suggested based on the
30-year high risk or a change in lifestyle.HEART (VASCULAR) AGE
Continuing the theme that some people (especially young
women or older people with only 1 elevated risk factor)
could have low 10-year probabilities, another risk feature
that Framingham investigators have presented is the so-
called heart (or vascular) age. The heart age is the age
that corresponds to a person with normal risk factors and
the same 10-year absolute risk. It is possible for a person to
have a low 10-year risk, but have a vascular age much older
than their chronological age. Consider the woman used in
the global CVD section of this paper. She was 61 with total
cholesterol of 230, HDL of 47, a nontreated systolic blood
pressure of 124, a nonsmoker, and was without diabetes.
The total number of points from Table 5 was 12 and her
10-year risk was 8.6%. Using Table 6, which converts
points into heart (vascular) age, we see that the heart age is
68. With respect to CVD risk, this woman has a heart age
or vascular system equivalent to a 68-year-old woman
who has normal risk values on all CVD risk factors. That is,
the 61-year-old woman has the same 10-year risk as a 68-
year-old woman whose risk factors are all at normal levels.19
TABLE 6. Heart age/vascular age for women
Points Heart Age, yrs Points Heart Age, yrs
Less than 1 Younger than 30 8 51
1 31 9 55
2 34 10 59
3 36 11 64
4 39 12 68
5 42 13 73
6 45 14 79
7 48 15þ Older than 80
j gREVIEW
20This heart age does give information as to the status of
the woman’s health that is not clear from the 10-year
risk alone.
The global CVD risk paper contains charts that can be
used to give heart age [32]. Again, the Framingham Web
page [64] can also supply these.
OTHER CVD RISK FUNCTIONS
Whereas the Framingham Risk Functions are the most
widely used for clinical guidelines, there are a number of
other important risk functions [91]. Of special note are the
European Systematic Coronary Risk Evaluation (SCORE)
function [92], the PROCAM (Prospective Cardiovascular
Münster) model [93], the QRISK function [94] and the
Reynolds functions [95,96]. The important SCORE func-
tion is actually a set of functions used in Europe and
consists of both region-speciﬁc and country-speciﬁc func-
tions. It is applicable for the risk estimation of only fatal
CVD events. The PROCAM function is applicable for CHD
deaths and nonfatal MI. The QRISK function applies to
CHD, stroke, and transient ischemic attack. The Reynolds
risk scores apply to CVD death, MI, stroke, and revascu-
larization. With regard to discrimination, most of these and
other risk functions perform in a similar fashion. Calibra-
tion, however, may vary and, as we have discussed, the
ability to recalibrate the Framingham Risk Functions is an
important feature. An informative review of CVD risk
functions discussing in depth their rationale, comparing
them in content and performance, discussing whether they
improve patient outcomes, and suggesting their future is
given by Cooney et al. [97].
WHAT IS NEXT?
The Framingham study has played a major leading role in
the development and dissemination of risk prediction
functions. The Framingham Risk Functions have been used
and tested in numerous settings. They do have validity and
transportability. In the United States, there are other
epidemiologic studies with similar data [98e100]. It is
logical to combine the data from these studies and produce
risk models that are applicable to most, if not all, of the
United States. This activity is underway. The models from
this effort will focus on short-term risks (10 years), butthey will also realize that long-term risk such as 30-year
risk and concepts such as heart (vascular) age are essen-
tial for quantifying and understanding risk. Further, the
possible addition of new variables added to improve
prediction must be pursued. In particular, genetic markers
offer tremendous possibilities [76]. Most important, it is
essential that these new models be used in treatment
guidelines [101]. Determining the best ways to convey
the risks, convert the risk to treatment action, and judge
the usefulness and success of these are imperative
[82,97,101e105]. The lessons that we have learned and
continue to learn from the Framingham study and the
development and implementation of its Framingham
Risk Functions can help bring success to these future
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